WATERTOWN, Mass., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the following upcoming investor conferences:
  • 17th Annual BIO CEO & Investor Conference on Monday, February 9th at 1:00 p.m. Eastern Time at the Waldorf Astoria Hotel in New York City
  • 2015 Leerink Global Healthcare Conference on Wednesday, February 11th at 3:55 p.m. Eastern Time at the Waldorf Astoria Hotel in New York City

Live audio webcasts of the presentations will be available on the company's website at http://ir.tphase.com/events.cfm.  Archived presentations will be available for 90 days.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Please visit www.tphase.com for more company information.
CONTACT: Investor Contacts:         Tetraphase Pharmaceuticals         Teri Dahlman         617-600-7040         tdahlman@tphase.com                  Media Contact:         Sam Brown Inc.         Mike Beyer         773-463-4211         beyer@sambrown.com                  Argot Partners         Susan Kim         212-600-1902         susan@argotpartners.com